drugset

drugset / Trial / NCT04088058

A Phase II Open-label Single-arm Study to Evaluate the Efficacy and Safety of ADSCs in Subjects With Liver Cirrhosis

NCT04088058 ↗

Phase 2 Unknown 20 enrolled Gwo Xi Stem Cell Applied Technology Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The aim of the investigators study was to investigate the safety and efficacy of autologous ADSCs for the clinical treatment of liver cirrhosis.

Timeline

Start: 2019-11-16
Primary completion: 2025-04-19
Completion: 2025-04-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GXHPC1	Cell therapy	1 ml	Other

Indications